Chaga for Gut Health
200 mg/kg Rat Model
Ethanolic extract of Inonotus obliquus at 200 mg/kg by oral administration showed antiulcer activity against ethanol-induced gastric mucosal ulceration in rats, without signs of toxicity or sensitivity. No human gastric ulcer trial has tested chaga.
Xin et al., Int J Med Mushrooms, 2019
Ethanol-induced ulcer model
standard rat gastric ulcer model in which chaga showed protective activity
NF-κB inhibition
macrophage-level mechanism relevant to gastric inflammation (Kim et al., 2007)
0 human trials
published for chaga in gastric ulcer, H. pylori eradication, or GERD
Xin et al., Int J Med Mushrooms, 2019
View as image ↗Gastric ulcers form when the balance between mucosal protective factors (mucus, bicarbonate, prostaglandins, adequate blood flow, epithelial renewal) and aggressive factors (gastric acid, pepsin, Helicobacter pylori, NSAIDs, alcohol, stress) shifts toward damage. Modern ulcer treatment centres on acid suppression (proton pump inhibitors, H2 receptor antagonists) and H. pylori eradication where indicated. Against this clinical backdrop, chaga (Inonotus obliquus) has one published rat gastric ulcer study showing antiulcer activity, supported by the broader preclinical anti-inflammatory evidence for chaga across multiple tissues.[1] No human trial has tested chaga for gastric ulcer treatment, H. pylori eradication, or non-ulcer dyspepsia. For the direct H. pylori evidence sibling, see chaga and helicobacter pylori: antimicrobial effects on stomach bacteria.
Key Takeaways
- Xin et al. (2019) administered ethanolic extract of Inonotus obliquus at 200 mg/kg by oral feed to rats with ethanol-induced gastric mucosal ulceration and documented effective antiulcer activity with no signs of toxicity or sensitivity (Xin et al., 2019)
- Chaga's anti-inflammatory activity in gastric tissue is mechanistically supported by NF-κB inhibition in LPS-stimulated macrophages (Kim et al., 2007) and by attenuation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ) in colitis models (Mishra et al., 2012)
- Orally administered aqueous I. obliquus extract preserved mucosal integrity in DSS-induced colitis in mice, with reduced oedema, reduced mucosal damage, and reduced crypt loss (Mishra et al., 2012)
- Chaga polysaccharides have documented broad-spectrum antiviral activity, including activity against feline herpesvirus and feline panleukopenia virus via blocking viral attachment; mechanistic relevance to viral contributors to gastric pathology (Tian et al., 2017)
- Comprehensive reviews (Fordjour et al., 2023; Ern et al., 2024) identify anti-inflammatory and gastroprotective activity among chaga's documented preclinical properties while flagging the absence of clinical trial data
- Three case reports of chaga-induced oxalate nephropathy and documented antiplatelet activity complicate the risk-benefit calculation in patients with gastric ulcers (who may already be on PPIs, NSAIDs, antiplatelet drugs, or anticoagulants)
Gastric Ulcer Pathophysiology: What a Gastroprotective Agent Must Do
The stomach's defensive architecture operates at multiple levels. The mucus gel layer, secreted by surface epithelial cells and foveolar glands, provides a physical barrier against luminal acid and pepsin. Bicarbonate secretion trapped within the mucus maintains a near-neutral pH at the epithelial surface despite acidic gastric contents. Mucosal blood flow delivers oxygen and nutrients and removes protons that have diffused across the barrier. Prostaglandins (primarily PGE2 and PGI2) maintain all three systems and drive epithelial renewal. Gastric epithelial cells turn over rapidly, providing continuous regeneration of the protective surface.
Aggressive factors disturb this balance. Alcohol, NSAIDs, and H. pylori each damage the mucus barrier, inhibit prostaglandin synthesis, or induce inflammation that further compromises defences. The standard rat gastric ulcer models use either ethanol (alcohol-type damage), indomethacin (NSAID-type damage), or pyloric ligation with aspirin (acid/NSAID combined) to create reproducible mucosal lesions that gastroprotective candidates can be tested against.
Xin et al. (2019) used the ethanol-induced model, which is particularly relevant to the anti-inflammatory and antioxidant mechanisms that chaga offers. Ethanol damage involves direct cytotoxic effects, oxidative stress, lipid peroxidation, leukocyte infiltration with release of pro-inflammatory cytokines, and disruption of the mucus-bicarbonate barrier.[1]
The Xin 2019 Study: Ethanolic Extract of Chaga in Rat Gastric Ulcer
Xin et al. (2019) prepared an ethanolic extract of Inonotus obliquus and tested its antiulcer activity in rats with ethanol-induced gastric mucosal ulceration.[1] The 200 mg/kg oral dose did not produce signs of toxicity or sensitivity in the rats, establishing tolerability at this dose. Oral administration of the extract exhibited antiulcer activity in the models used, which the authors attributed to biologically active compounds including the phenolic compounds, triterpenoids, and polysaccharides documented across the I. obliquus literature.
The study framed its findings as confirming traditional uses of chaga in treating gastrointestinal ailments. The methodological limitations are standard for single-centre preclinical gastroprotection studies: one dose tested, one ulcer model, one species, relatively short-term exposure, and endpoints focused on gross ulcer scoring rather than detailed biochemical characterisation of mucus gene expression, prostaglandin synthesis, or epithelial proliferation. The positive result is informative but does not establish the specific mechanism of action or predict efficacy in other ulcer models (indomethacin, aspirin, stress, H. pylori).
Mechanistic Support from Related Chaga Studies
Gastric ulcer pathology shares inflammatory mechanisms with intestinal inflammation. The cytokine cascade (TNF-α, IL-1β, IL-6) contributes to neutrophil infiltration, reactive oxygen species generation, and extension of mucosal damage in both contexts. Chaga's documented anti-inflammatory profile in other tissue inflammation models provides mechanistic support for the Xin 2019 ulcer finding.
Kim et al. (2007) demonstrated that ethanol extract of I. obliquus suppressed LPS-induced NF-κB activation in RAW 264.7 macrophages, reducing iNOS, COX-2, TNF-α, IL-1β, and IL-6 expression.[2] NF-κB activation drives inflammation in gastric mucosa during ulcer formation. A compound that reliably inhibits NF-κB in macrophages has mechanistic relevance to gastric inflammation, though direct demonstration in gastric tissue would be required for definitive attribution.
Mishra et al. (2012) extended the anti-inflammatory signal to gut mucosa. Oral aqueous I. obliquus extract in DSS-induced colitis in mice suppressed oedema, mucosal damage, crypt loss, iNOS, myeloperoxidase, and the mRNA expression of TNF-α, IL-1β, IL-6, and IFN-γ.[3] The colon is not the stomach, but both are gastrointestinal mucosal surfaces subject to inflammation-driven damage, and chaga's anti-inflammatory signal was preserved at the tissue level in the gut context.
Antioxidant Mechanisms Relevant to Ethanol-Induced Damage
Ethanol-induced gastric ulcer involves substantial oxidative stress. Ethanol metabolism generates reactive oxygen species, depletes glutathione, and induces lipid peroxidation in gastric epithelium. Antioxidant compounds that preserve mucosal glutathione content, increase SOD/CAT/GPx activity, and reduce MDA formation are mechanistically relevant to protecting against this damage.
Chaga's antioxidant profile is extensive. Sun et al. (2008) documented increased catalase, SOD, and glutathione peroxidase activity and decreased MDA in diabetic mouse liver after chaga culture broth administration. Hong et al. (2015) demonstrated that I. obliquus water extract preserved glutathione content and reduced MDA formation in primary cultured rat hepatocytes exposed to tert-butyl hydroperoxide. Debnath et al. (2013) showed that chaga grown on germinated brown rice exhibited strong antioxidant activity in H2O2-stimulated mouse liver. None of these studies specifically measured gastric mucosal antioxidant enzyme changes, but the consistent antioxidant signal across tissues supports the plausibility of chaga's gastroprotective mechanism in the ethanol model.
For the combined detox-and-antioxidant picture, see chaga and liver detoxification enzymes: research review.
Broad-Spectrum Antiviral Activity: A Tangential but Relevant Angle
Tian et al. (2017) identified chaga polysaccharide as a broad-spectrum antiviral compound active against feline calicivirus, feline herpesvirus 1, feline influenza virus H3N2 and H5N6, feline panleukopenia virus, and feline infectious peritonitis virus in cell culture.[4] The mechanism involved direct blocking of viral binding and attachment. Several of these feline viruses cause gastrointestinal disease with gastric and intestinal mucosal damage. The finding is tangential to human gastric ulcer but documents that chaga polysaccharides can interfere with viral-mucosal interactions, which is relevant to any virally contributed gastric pathology.
What the Reviews Say About Chaga Gastroprotection
Fordjour et al. (2023) and Ern et al. (2024) both include gastroprotective activity among chaga's documented preclinical properties, drawing on the ethanol-induced ulcer study and related inflammation and antioxidant evidence.[5][6] Both reviews frame the evidence as entirely preclinical, with no randomised controlled trial testing chaga for any human gastric condition (peptic ulcer disease, H. pylori gastritis, functional dyspepsia, gastroesophageal reflux disease, or NSAID-associated gastropathy).
The absent clinical translation is the central gap. A phase 1 or phase 2 trial testing chaga as an adjunct to standard care (PPI plus antibiotic triple or quadruple therapy for H. pylori) in patients with confirmed peptic ulcer disease would be scientifically reasonable given the preclinical mechanistic rationale. Such a trial has not been registered or published.
Safety Considerations Specific to Ulcer Populations
Patients with peptic ulcer disease or gastric pathology face several safety considerations relevant to chaga use:
Concurrent medications: Patients with ulcers are frequently on proton pump inhibitors (reducing gastric acid, altering protein digestion and vitamin B12 absorption), NSAIDs (which contributed to the ulcer in many cases), low-dose aspirin (for cardiovascular prevention), anticoagulants, or antibiotic combinations. Chaga's documented antiplatelet activity (Tao & Feng, 1990 for Ganoderma; Hyun et al., 2006 for chaga Trp-Gly-Cys peptide) adds bleeding risk to patients already on aspirin or anticoagulants with an ulcer lesion that could bleed.
Renal risk from oxalate: Three published case reports document chaga-induced oxalate nephropathy from long-term high-dose use. Patients with gastric pathology may have complicating renal considerations from NSAID history or co-morbid chronic kidney disease, making oxalate-driven renal risk particularly relevant.
Helicobacter pylori co-treatment: Standard H. pylori eradication regimens include combinations of clarithromycin, amoxicillin, metronidazole, levofloxacin, and bismuth, alongside high-dose PPIs. No drug interaction study has characterised chaga's compatibility with any of these. The pharmacokinetic risk is unquantified.
For the full safety picture, see can you take chaga long-term? safety considerations.
The Active Compound Landscape for Gastroprotection
The compound classes most likely to drive chaga's gastroprotective signal, based on mechanistic plausibility combined with documented chaga content, are:
Triterpenoids (inotodiol, trametenolic acid): Lanostane triterpenoids can suppress NF-κB activation and reduce inflammatory cytokine production. Kim et al. (2020) quantified inotodiol at 153.9–194.1 mg/g and trametenolic acid at 94.5–106.3 mg/g in chaga triterpenoid fractions, with higher content in the outer canker.[7] Whether oral dosing delivers these triterpenoids to gastric mucosa at mechanistically active concentrations has not been characterised.
Polyphenols (inonoblins, phelligridins): Lee et al. (2007) isolated inonoblins A, B, C and phelligridins D, E, G from chaga, all with antioxidant activity against ABTS, DPPH, and superoxide radicals.[8] Gastric antioxidant protection is mechanistically relevant to ethanol-induced ulcers specifically.
β-Glucans: Fungal cell wall polysaccharides with Dectin-1 engagement and innate immune modulation; these are less likely to directly protect gastric epithelium but may contribute through systemic anti-inflammatory effects.
Melanins: Chaga's characteristic melanin content provides antioxidant and polyanionic binding activity; direct gastric mucosal effects have not been characterised.
What the Evidence Supports and What It Does Not
| Question | Evidence | Confidence |
|---|---|---|
| Does chaga show gastroprotective activity in rat ulcer models? | Yes: ethanolic extract 200 mg/kg effective in ethanol-induced gastric ulcer (Xin et al., 2019) | Moderate (preclinical, single model) |
| Does chaga reduce gastric inflammation at the tissue level? | Inferential from macrophage NF-κB inhibition (Kim et al., 2007) and colitis model cytokine suppression (Mishra et al., 2012) | Low to moderate |
| Does chaga protect against NSAID-induced or stress-induced ulcers? | Not tested: no published study using these models | None |
| Has chaga been tested in humans with peptic ulcer disease? | No randomised controlled trial published | None |
| Does chaga help with Helicobacter pylori eradication? | No published trial in humans; see dedicated cluster sibling on chaga and H. pylori | None |
| Is chaga safe for ulcer patients? | Unquantified: antiplatelet activity and oxalate nephropathy risks complicate the picture | Precautionary |
The Bottom Line
Chaga (Inonotus obliquus) ethanolic extract at 200 mg/kg showed antiulcer activity in rats with ethanol-induced gastric mucosal ulceration, without signs of toxicity (Xin et al., 2019). Mechanistic support comes from chaga's documented NF-κB inhibition (Kim et al., 2007), anti-inflammatory cytokine suppression in colitis models (Mishra et al., 2012), and antioxidant enzyme modulation (Sun 2008; Hong 2015; Debnath 2013). No randomised controlled trial has tested chaga in humans with peptic ulcer disease, H. pylori gastritis, or NSAID-associated gastropathy. Patients with gastric ulcers face compounded safety considerations including chaga's antiplatelet activity and documented oxalate nephropathy risk.
Frequently Asked Questions
Sources & References
- 1RTHM-00600·Xin, Xin et al. (2019). “Assessment of the Gastroprotective Effect of the Chaga Medicinal Mushroom, Inonotus obliquus (Agaricomycetes), Against the Gastric Mucosal Ulceration Induced by Ethanol in Experimental Rats..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 2RTHM-00117·Kim, Ho-Gyoung et al. (2007). “Ethanol extract of Inonotus obliquus inhibits lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells..” Journal of medicinal food.Study breakdown →PubMed →↩
- 3RTHM-00258·Mishra, Siddhartha Kumar et al. (2012). “Orally administered aqueous extract of Inonotus obliquus ameliorates acute inflammation in dextran sulfate sodium (DSS)-induced colitis in mice..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
- 4RTHM-00492·Tian, Jin et al. (2017). “Identification of Inonotus obliquus polysaccharide with broad-spectrum antiviral activity against multi-feline viruses..” International journal of biological macromolecules.Study breakdown →PubMed →↩
- 5RTHM-01694·Fordjour, Eric et al. (2023). “Chaga mushroom: a super-fungus with countless facets and untapped potential..” Frontiers in pharmacology.Study breakdown →PubMed →↩
- 6RTHM-01886·Ern, Phoebe Tee Yon et al. (2024). “Chaga Therapeutic Properties: What This 2024 Review Actually Shows.” Mycology.Study breakdown →PubMed →↩
- 7RTHM-01218·Kim, Jaecheol et al. (2020). “Composition of Triterpenoids in Inonotus obliquus and Their Anti-Proliferative Activity on Cancer Cell Lines..” Molecules (Basel.Study breakdown →PubMed →↩
- 8RTHM-00118·Lee, In-Kyoung et al. (2007). “New antioxidant polyphenols from the medicinal mushroom Inonotus obliquus..” Bioorganic & medicinal chemistry letters.Study breakdown →PubMed →↩